AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01433172 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase II - GM.CD40L.CCL21 Vaccinations
Description: This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
Study NCT01361893 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle Counseling
Description: We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
Study NCT02598206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Description: Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets.
Study NCT00728273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: worm treatment and multiple micronutrient fortified biscuits
Description: A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin.
Study NCT04548336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: Motor imagery group will have to imagine motor gestures of static and dynamic balance
Study NCT04548336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: Action observation group will have to observe static and dynamic equilibrium motor gestures
Study NCT04548336 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This group will watch a video of nature without a human component.
Study NCT00357734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Described elsewhere
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octreotide
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mixed Amino Acids
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mixed Amino Acids
Description: Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [2H5]phenylalanine
Description: Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [2H5]phenylalanine
Description: Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [1-13C]leucine
Description: Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
Study NCT02305069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [1-13C]leucine
Description: Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
Study NCT00996073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Interbody Fusion with Autograft
Description: Single Dose Autograft Surgical Implantation
Study NCT00996073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar Interbody Fusion with NeoFuse
Description: Single Dose NeoFuse Surgical Implantation
Study NCT02478606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Stretching Exercises
Description: The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
Study NCT01172860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoVe endoscopic electroporation
Description: The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
Study NCT03334201 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Western Diet
Description: high fat (40%), high sugar (25%) and low fiber (15g/day)
Study NCT03334201 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-Western Diet
Description: low fat (25%), low sugar (15%), high fiber (30g/day)
Study NCT01476527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
Study NCT02923557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirarubicin
Description: single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
Study NCT00386191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990C)
Description: oral administration
Study NCT01970306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatriStem PSM
Description: All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
Study NCT02348996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: status of overhydration determine by BCM once a week to determine dry weight
Study NCT02348996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluation
Description: Doctors or nurses will evaluate patients on a daily basis and determine dry weight
Study NCT01470456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR3419
Description: Pharmaceutical form:solution for infusion Route of administration: Intravenous
Study NCT01470456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study NCT02782286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The patients randomised to this arm will receive 30 mg intravenous ketorolac.
Study NCT02782286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
Study NCT02733523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Sentirnos bien (Feeling well)
Description: Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~1. Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~2. Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~3. Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food.
Study NCT04223713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TriRec
Description: Trileaflet Reconstruction of the Aortic Valve
Study NCT04223713 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Description: Biological Prosthesis, Device: Edwards Perimount
Study NCT03676972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LithoVue Ureteroscope System
Description: The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
Study NCT00458120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
Study NCT00987506 — intervention group
Intervention type: DEVICE
Intervention: XIENCE V®
Description: Participants with placement of a XIENCE V® EESS
Study NCT00458120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2/4delta30(ME)
Description: Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
Study NCT00458120 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Description: Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
Study NCT02294058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Capsules for oral administration once a day
Study NCT02294058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Administered by intramuscular injection once a week
Study NCT02294058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ozanimod
Description: Matching placebo capsules administered orally once a day
Study NCT02294058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to interferon beta-1a
Description: Placebo intramuscular injection once a week
Study NCT01950403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide acetate
Description: Given PO
Study NCT01950403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01950403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04635956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: 6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
Study NCT01256229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implantation
Description: This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
Study NCT01950403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT01950403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01950403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01256229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cochlear implantation
Description: This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
Study NCT04363879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratch with Pipelle curette
Description: For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
Study NCT04363879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratch with Shepard catheter
Description: For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
Study NCT01908452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyridoxine
Description: 1200 mg/d during 12 weeks
Study NCT01908452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 1200 mg/d during 12 weeks
Study NCT00700713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, IM
Study NCT00700713 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, IM
Study NCT03576378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BrentuximabVedotin (BV)
Description: All patients will be treated with 6 cycles of BV-EPEM
Study NCT01745445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent chemo-radiotherapy arm
Description: VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
Study NCT00748098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1838262 Extended Release Tablets
Description: GSK1838262 extended release tablets
Study NCT01256229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aids
Description: This is the conventional therapy for deaf children with developmental delays.
Study NCT03763019 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional rehabilitation
Description: Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
Study NCT03763019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
Study NCT03763019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory rehabilitation
Description: Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
Study NCT03407755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular gas
Description: Participants randomized to either air or SF6 gas in the anterior chamber.
Study NCT03407755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular gas
Description: Participants randomized to either air or SF6 gas in the anterior chamber.
Study NCT04015206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy
Description: Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
Study NCT04015206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Interpersonal Psychotherapy
Description: Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
Study NCT03708978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mammography
Description: When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
Study NCT02527590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations(allodynic area)
Description: 2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
Study NCT02527590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations (healthy area)
Description: 2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
Study NCT02527590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations no auditory masking
Description: 2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
Study NCT02527590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no stimulation (control)
Description: no stimulation (control condition): air jet directed beside the hand
Study NCT02527590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations with audidory masking
Description: 2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
Study NCT02292719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet
Study NCT02292719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet
Study NCT02292719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study NCT03081130 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous laser irradiation treatment
Description: control group
Study NCT03078504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous renal replacement therapy using System One (TM) setup (Nxstage)
Description: Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
Study NCT04171050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic
Description: Local anesthesia injections
Study NCT04171050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Nerve Block plus anesthesia
Description: Local anesthesia injections plus a pudendal nerve block
Study NCT02842294 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Study NCT04651868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)
Study NCT04651868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A 210 mins intravenous infusion with isotonic NaCl